Celyad Signs an Exclusive License Agreement with Horizon Discovery for its shRNA Technology

 Celyad Signs an Exclusive License Agreement with Horizon Discovery for its shRNA Technology

Celyad Signs an Exclusive License Agreement with Horizon Discovery for its shRNA Technology

 Shots:

  • Celyad to get hold of Horizon’s shRNA technology for generation and development of allogenic CAR-T therapies
  • shRNA (Short hairpin) technology is based on DNA and contains a selectable marker to allow elimination of cells that didn’t transfected or transduced
  • Celyad’s novel CYAD-101 is a non-gene-edited allogeneic CAR-t candidate, NKG2D-based is developed by using the TIM (TCR Inhibiting Molecule)

Click here to read full press release/ article | Ref: Celyad  | Image: Awexexportbe

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post